ClinicalTrials.Veeva

Menu

Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea

Allergan logo

Allergan

Status

Completed

Conditions

Urinary Bladder, Overactive
Urinary Incontinence

Treatments

Biological: botulinum toxin Type A

Study type

Observational

Funder types

Industry

Identifiers

NCT02010788
191622-134

Details and patient eligibility

About

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB) not adequately controlled by anticholinergic drugs.

Enrollment

523 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

-Patients with urinary incontinence due to NDO or OAB treated with BOTOX® as per local standard of care in clinical practice.

Exclusion criteria

-None.

Trial design

523 participants in 1 patient group

BOTOX®
Description:
Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
Treatment:
Biological: botulinum toxin Type A

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems